Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update

Alexandru Burlacu, Simonetta Genovesi, Alberto Ortiz, Christian Combe, Carlo Basile, Daniel Schneditz, Frank van der Sande, Grigore T. Popa, Cornel Morosanu, Adrian Covic*, ERA-EDTA EUDIAL Working Grp

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

Original languageEnglish
Pages (from-to)923-933
Number of pages11
JournalNephrology Dialysis Transplantation
Volume34
Issue number6
DOIs
Publication statusPublished - Jun 2019

Keywords

  • anticoagulants
  • antiplatelets
  • dialysis
  • G5D chronic kidney disease
  • guidelines
  • LOW-MOLECULAR-WEIGHT
  • ATRIAL-FIBRILLATION PATIENTS
  • ACUTE MYOCARDIAL-INFARCTION
  • DUAL ANTIPLATELET THERAPY
  • HEMODIALYSIS-PATIENTS
  • RENAL-DISEASE
  • WARFARIN USE
  • UNFRACTIONATED HEPARIN
  • VENOUS THROMBOEMBOLISM
  • FOCUSED UPDATE

Cite this

Burlacu, A., Genovesi, S., Ortiz, A., Combe, C., Basile, C., Schneditz, D., van der Sande, F., Popa, G. T., Morosanu, C., Covic, A., & ERA-EDTA EUDIAL Working Grp (2019). Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. Nephrology Dialysis Transplantation, 34(6), 923-933. https://doi.org/10.1093/ndt/gfz040